Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP10 | Q14694 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | USP13 | Q92995 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 0.67 |
| ▸ | CNR2 | P34972 | 2/20 | 0.67 |
| ▸ | EGFR | P00533 | 6/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.56 |
| ▸ | GALR3 | O60755 | 1/20 | 0.55 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1068401 | 1.00 | USP10 (1.00) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL9921341 | 0.92 | USP10 (0.84) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL13170963 | 0.92 | USP10 (0.84) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL13192047 | 0.89 | USP10 (0.80) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL9921506 | 0.89 | USP10 (0.80) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL7469214 | 0.87 | USP10 (0.76) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL9921355 | 0.84 | USP10 (0.71) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL9921511 | 0.83 | USP10 (0.70) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL9921345 | 0.82 | USP10 (0.69) | USP10PIK3C3USP13CNR1CNR2 | |
| SCHEMBL17557755 | 0.81 | CNR1 (1.00) | USP10PIK3C3USP13CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | claimed |
| US-20250152531-A1 | INHIBITORS OF AUTOPHAGY AND DCAR-1 AS NOVEL ANTHELMINTIC AGENTS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES | 2025-05-15 | — | — | US | claimed |
| US-20250064804-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2025-02-27 | — | — | US | claimed |
| US-12233036-B2 | Inhibitors of autophagy and DCAR-1 as novel anthelmintic agents | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2025-02-25 | — | — | US | claimed |
| CN-119185316-A | Use of PARPi sensitizer in treating malignant tumor | 中国医学科学院肿瘤医院 | 2024-12-27 | — | — | CN | claimed |
| US-20240400986-A1 | MEMBRANE BOUND COMPOSITIONS AND METHODS RELATING TO SAME | FLAGSHIP PIONEERING INNOVATIONS VII, LLC | 2024-12-05 | — | — | US | claimed |
| EP-4444310-A2 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2024210503-A1 | COMPOSITION CONTAINING USP10 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF OBESITY AND LIPID-RELATED METABOLIC DISEASES | 연세대학교 산학협력단 | 2024-10-10 | — | — | WO | claimed |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | claimed |
| EP-4402244-A1 | MEMBRANE BOUND COMPOSITIONS AND METHODS RELATING TO SAME | Flagship Pioneering Innovations VII, LLC (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2023108110-A2 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2023043941-A1 | MEMBRANE BOUND COMPOSITIONS AND METHODS RELATING TO SAME | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2023-03-23 | — | — | WO | claimed |
| US-20230011398-A1 | COMBINATION THERAPY APPROACH TO ELIMINATE HIV INFECTIONS | THE METHODIST HOSPITAL SYSTEM | 2023-01-12 | — | — | US | claimed |
| EP-4114946-A1 | METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPY | Regeneron Pharmaceuticals, Inc. (US) | 2023-01-11 | — | — | EP | claimed |
| CN-115485385-A | Methods and compositions for sensitizing tumor cells to immunotherapy | 瑞泽恩制药公司 | 2022-12-16 | — | — | CN | claimed |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY | 2022-10-13 | — | — | US | claimed |
| EP-4048292-A1 | ENGINEERED NATURAL KILLER CELLS AND METHODS FOR USING THE SAME IN IMMUNOTHERAPY AND AUTOPHAGY INHIBITION TECHNIQUES | Purdue Research Foundation (US) | 2022-08-31 | — | — | EP | claimed |
| US-12636370-B2 | Combination therapy for treatment of cancer | INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-26 | — | — | US | disclosed |
| EP-3956813-A1 | DETECTION, PREDICTION, AND CLASSIFICATION FOR OCULAR DISEASE | Boyd, Shelley (CA) | 2022-02-23 | — | — | EP | disclosed |
| US-20220025461-A1 | METHODS OF DETECTING, PREVENTING, REVERSING, AND TREATING NEUROLOGICAL DISEASES | WASHINGTON UNIVERSITY (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636370-B2 | Combination therapy for treatment of cancer | RB1, MDM2, PHKB | USP10 540/4885PIK3C3 1438/4885USP13 645/4885 |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | MCL1, BAX, CASP3 | USP10 1145/4885PIK3C3 3684/4885USP13 1603/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | USP10 987/4885PIK3C3 1858/4885USP13 2724/4885 |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | ECHS1, GLS2, OAT | USP10 2874/4885PIK3C3 4609/4885USP13 3056/4885 |
| US-20250064804-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | NRAS, BRAF, BECN1 | USP10 2024/4885PIK3C3 420/4885USP13 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.